Cancer drugs are coming onto the market without clear evidence they improve the quality or quantity of patients’ lives, according to an evaluation of drug approvals by the European Medicines Agency. The study of 48 cancer drugs approved for 68 indications between 2009 and 2013 found a significant survival benefit had been demonstrated in only 35% of ...
Time to raise the bar of proof for cancer drugs
By Mardi Chapman
5 Oct 2017